| Bioactivity | AAK1-IN-3 TFA, a quinoline analogue, is a brain-penetrant adaptor protein 2-associated kinase 1 (AAK1) inhibitor with an IC50 of 11 nM. AAK1-IN-3 has the potential for neuropathic pain research[1]. |
| Invitro | AAK1-IN-3 (compound (R)-31) TFA is brain-penetrant kinase inhibitors with a B/P ratio of 1.3[1]. AAK1-IN-3 TFA inhibits AAK1 in HEK293 cells (IC50=108 nM)[1]. |
| In Vivo | AAK1-IN-3 (compound (R)-31; 30 mg/kg; sc; signle dose) TFA causes a 46% reduction of μ2 phosphorylation in C57BL6 mice[1]. |
| Name | AAK1-IN-3 TFA |
| Formula | C24H22F6N4O4 |
| Molar Mass | 544.45 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Richard A Hartz, et al. Bicyclic Heterocyclic Replacement of an Aryl Amide Leading to Potent and Kinase-Selective Adaptor Protein 2-Associated Kinase 1 Inhibitors. J Med Chem. 2022 Mar 10;65(5):4121-4155. |